Valuation: Evolus, Inc.

Market Cap 487M 433M 402M 364M 684M 46.12B 695M 4.82B 1.89B 24.13B 1.83B 1.79B 76.99B P/E 2026 *
-15x
P/E 2027 * -47.2x
Enterprise Value 608M 541M 501M 454M 854M 57.58B 868M 6.02B 2.36B 30.13B 2.28B 2.23B 96.12B EV / Sales 2026 *
1.82x
EV / Sales 2027 * 1.56x
Free-Float
85.03%
Yield 2026 *
-
Yield 2027 * -
1 day+0.14%
1 week-1.86%
Current month-7.88%
1 month-6.23%
3 months+32.91%
6 months+45.08%
Current year+10.83%
1 week 7.02
Extreme 7.015
7.71
1 month 6.91
Extreme 6.9127
8.51
Current year 3.86
Extreme 3.86
9.31
1 year 3.86
Extreme 3.86
9.31
3 years 3.86
Extreme 3.86
17.82
5 years 3.86
Extreme 3.86
17.82
10 years 2.85
Extreme 2.85
39.5
Manager TitleAgeSince
Chief Executive Officer 48 06/05/2018
Director of Finance/CFO 48 08/09/2025
Chief Operating Officer - 01/09/2022
Director TitleAgeSince
Chairman 63 01/01/2018
Director/Board Member 71 12/02/2018
Director/Board Member 48 06/05/2018
Date Insider Type Main position Quantity % Market Cap. Importance
2/9/26 Sell

Chief Executive Officer

-105,108 0.1625%
20/3/26 Sell

Chief Executive Officer

13,669 0.0211%
20/3/26 Sell

Chief Technology Officer

3,119 0.0048%
Change 5-day change 1-year change 3-year change Capi.($)
+0.14%-1.86%+10.16%-5.63% 487M
+3.49%+10.04%+58.68%+119.56% 1,144B
+2.19%+4.32%+33.88%+69.52% 625B
+2.26%+5.37%+24.57%+97.69% 511B
+2.58%+8.37%+38.71%+63.14% 377B
+3.25%+4.45%+71.80%+44.44% 366B
+1.85%+6.04%+21.47%+49.17% 291B
+1.76%+6.07%+0.43%+20.98% 262B
+3.29%+6.32%+44.71%+57.43% 237B
+2.25%+5.81%+27.13%+101.17% 194B
Average +1.85%+3.58%+33.15%+61.75% 400.84B
Weighted average by Cap. +1.43%+4.68%+40.91%+80.66%

Financials

2026 *2027 *
Net sales 334M 297M 276M 250M 469M 31.66B 477M 3.31B 1.3B 16.57B 1.25B 1.23B 52.85B 392M 349M 324M 293M 551M 37.15B 560M 3.88B 1.53B 19.44B 1.47B 1.44B 62.03B
Net income -31.58M -28.11M -26.05M -23.61M -44.36M -2.99B -45.11M -313M -123M -1.57B -118M -116M -4.99B -9.05M -8.05M -7.46M -6.76M -12.71M -857M -12.92M -89.56M -35.18M -449M -33.94M -33.23M -1.43B
Net Debt 121M 108M 99.82M 90.45M 170M 11.46B 173M 1.2B 471M 6B 454M 444M 19.14B 126M 112M 104M 94.19M 177M 11.94B 180M 1.25B 490M 6.25B 473M 463M 19.93B
Projected Income Statement - Annual - Evolus, Inc.
Logo Evolus, Inc.
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Employees
353
Date Price Change Volume
20/10/26 US$7.370 +0.14% 447,832
19/10/26 US$7.360 +3.66% 517,872
16/10/26 US$7.100 -6.21% 761,678
15/10/26 US$7.570 +4.85% 901,465
14/10/26 US$7.220 -3.86% 1,007,550
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Evolus, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.370USD
Average target price
15.00USD
Spread / Average Target
+103.53%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Evolus, Inc.
  1. Stock Market
  2. Stocks
  3. EOLS Stock